Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Cómo se absorbe, metaboliza y elimina del organismo [14C]-DSP-5336 tras una dosis oral única en pacientes con cánceres hematológicos avanzados

29 de septiembre de 2026 actualizado por: Sumitomo Pharma America, Inc.

Un estudio de fase 1, de etiqueta abierta, de la absorción, metabolismo y excreción de DSP-5336 tras una dosis oral única en pacientes con leucemia aguda refractaria o recidivante, síndrome mielodisplásico, mieloma múltiple o neoplasias mieloproliferativas

The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after available standard therapies.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

8

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27514
        • University of North Carolina
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • MD Anderson Cancer Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Male or female, of any race, ≥ 18 years of age. Female patients must be surgically sterile or postmenopausal. Male patients must be permanently sterile or agree to use contraception.
  • Have an advanced hematological malignancy that is relapsed, refractory, or has progressed following receipt of standard and available treatments.
  • Any prior pre-treatment toxicities resolved to ≤Grade 1 prior to enrolment, with exception of ≤Grade 2 alopecia or neuropathy.
  • Adequate kidney and liver function
  • ECOG performance status of ≤ 2.
  • Able to attend the required study visits, including the confinement period for monitoring and collection of bowel movements and micturition.
  • Able to comprehend and are willing to sign the ICF and abide by the study restrictions.

Exclusion Criteria:

  • Histologic diagnosis of acute promyelocytic leukemia.
  • Abnormal ECG that is clinically significant, such as QTcF > 480 msec. QT interval correction can be performed in the case of bundle branch block.
  • History of torsades de pointes.
  • Left ventricular ejection fraction ≤ 45%, as determined by echocardiogram.
  • Have any concurrent conditions that could pose an undue risk or interfere with interpretation of the study results, including, but not limited to clinically significant non-healing or healing wounds, concurrent congestive heart failure, unstable angina, cardiac arrhythmia requiring treatment (excluding asymptomatic atrial fibrillation), myocardial infarction within 6 months, acute coronary syndrome within 6 months, significant pulmonary disease (shortness of breath at rest or on mild exertion; eg, due to concurrent severe obstructive pulmonary disease, hypertension not controlled with concomitant medication, or diabetes mellitus with > 2 episodes of ketoacidosis in the prior 6 months).
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed).
  • History or evidence of severe dysphagia, short-gut syndrome, gastroparesis, gastrointestinal tract disease, malabsorption syndrome, the requirement for intravenous alimentation, gastric/jejunal feeds, any uncontrolled gastrointestinal disease, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally, including the inability to swallow oral medication
  • Have cognitive, psychological, or psychosocial impediment that would impair their ability to receive therapy according to the protocol or would adversely affect their ability to comply with the informed consent process, protocol, or protocol-required visits and procedures.
  • History of bowel obstruction, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of check-in, unless approved by the investigator and medical monitor.
  • Active and uncontrolled bacterial, viral, or fungal infection requiring parenteral therapy.
  • Positive hepatitis panel and/or positive human immunodeficiency virus test indicative of active infection. Patients whose results are compatible with prior immunization may be included.
  • Undergone HSCT, chimeric antigen receptor cell therapy, or other modified T-cell therapy within 60 days prior to dosing.
  • Received donor lymphocyte infusion within 28 days prior to dosing, receiving immunosuppressive therapy post-HSCT, or have clinically active GVHD or GVHD requiring active medical intervention other than the use of topical steroids for ongoing cutaneous GVHD.
  • Received systemic calcineurin inhibitors within 2 weeks prior to dosing.
  • Received other anticancer drugs or other investigational treatment within 14 days or 5 half-lives, whichever is shorter, prior to dosing.
  • Major surgery within 28 days prior to dosing.
  • Any known intolerance or hypersensitivity to components of the study intervention.
  • Patients who have previously been dosed in > 2 radiolabeled drug studies in the last 12 months. For patients who have previously been dosed in ≤ 2 radiolabeled drug studies within the last 12 months, the previous radiolabeled dose must be at least 4 months prior to check-in to the study site where exposures are known to the investigator or 6 months prior to check-in to the study site for a radiolabeled drug study where exposures are not known to the investigator.
  • Poor peripheral venous access.
  • Patients with exposure to significant diagnostic or therapeutic radiation or current employment in a job requiring radiation exposure monitoring within 12 months prior to check-in.
  • Patients who, in the opinion of the investigator or designee, should not participate in this study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: DSP-5336 tablets and [14C]-DSP-5336 solution

Part 1

tablet

oral solution

Experimental: Optional Continued Access

Part 2

tablet

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Total recovery of radioactivity in urine as percentage of total radioactive dose of [14C]-DSP-5336
Periodo de tiempo: Day 1 to 4, max 7 days if less than 90% is collected by Day 4

The percentage of dose excreted in urine

Day 1 to 4, max 7 days if less than 90% is collected by Day 4
Total recovery of radioactivity in fecal waste as percentage of total radioactive dose of [14C]-DSP-5336
Periodo de tiempo: Day 1 to 4, max 7 days if less than 90% is collected by Day 4

The percentage of dose excreted in fecal waste

Day 1 to 4, max 7 days if less than 90% is collected by Day 4
Total recovery of radioactivity in excreta balance as percentage of total radioactive dose of [14C]-DSP-5336
Periodo de tiempo: Day 1 to 4, max 7 days if less than 90% is collected by Day 4

The percentage of dose excreted in combined urine and fecal waste

Day 1 to 4, max 7 days if less than 90% is collected by Day 4
Relative abundance (mean value) of [14C]-DSP-5336
Periodo de tiempo: 4 days, max 7 days

Plasma samples will be analyzed for [14C]-DSP-5336 and its metabolites.

4 days, max 7 days

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Area under the plasma concentration time profile from time zero to time of the last quantifiable concentration (AUClast) of [14C]-DSP-5336
Periodo de tiempo: 4 days, max 7 days

The determination of AUClast using the linear/log trapezoidal rule

4 days, max 7 days
Cmax for the relative bioavailability of [14C]-DSP-5336
Periodo de tiempo: 4 days, max 7 days

Analysis of the maximum concentration (Cmax) of the relative bioavailability of [14C]-DSP-5336 utilizing the ratio of the adjusted geometric means

4 days, max 7 days
t(1/2) of [14C]-DSP-5336
Periodo de tiempo: 4 days, max 7 days

Elimination half-life (t[1/2]) of [14C]-DSP-5336

4 days, max 7 days
Ratio of plasma to whole blood total radioactivity
Periodo de tiempo: 4 days, max 7 days

The fraction of [14C]-DSP-5336 radioactivity associated with whole blood and plasma and with red blood cells and other cellular components of whole blood was determined by using the concentration of [14C]-DSP-5336 radioactivity in whole blood and plasma

4 days, max 7 days
Number of participants with adverse events and serious adverse events
Periodo de tiempo: 30 days

Safety of DSP-5336 by reporting of AEs and SAEs

30 days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

26 de marzo de 2026

Finalización primaria (Actual)

11 de agosto de 2026

Finalización del estudio (Actual)

4 de septiembre de 2026

Fechas de registro del estudio

Enviado por primera vez

6 de febrero de 2026

Primero enviado que cumplió con los criterios de control de calidad

24 de febrero de 2026

Publicado por primera vez (Actual)

2 de marzo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

29 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • DSP-5336-102

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir